Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Pan-caspase Inhibitor IDN-7314 Reduces Inflammation and Liver Injury in Mouse Model of PSC SAN DIEGO , April 09, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced an
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Biopsy-based Proof of Concept in Liver Fibrosis and Cirrhosis Supports Further Evaluation   Conference Call and Webcast Presentation at 4:30 p.m. ET Today  SAN DIEGO , April 04, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates
SAN DIEGO , March 07, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31,
View HTML
Toggle Summary Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- At three upcoming investor conferences in March, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) President, Chief Executive Officer and co-founder, Steven J. Mento , Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2017 , after the market close on Wednesday, March 7, 2018 .
View HTML
Toggle Summary Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR Patients
SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will host a conference call and webcast presentation at 12:00 p.m. ET on Tuesday, February 20 , with liver disease expert Paul Pockros , M.D., director of the Liver Disease Center at Scripps Clinic in La Jolla,
View HTML
Toggle Summary Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts and Strategic Initiatives at Upcoming Investor Events
SAN DIEGO , Feb. 05, 2018 (GLOBE NEWSWIRE) -- In a presentation and in scheduled meetings with members of the investment community in New York next week, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) President, Chief Executive Officer and co-founder, Steven J.
View HTML
Toggle Summary Conatus to Present at Stifel Healthcare Conference
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Stifel 2017 Healthcare Conference in New York at 11:45 a.m. ET on Wednesday, November 15, 2017.
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2017,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results
SAN DIEGO, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2017, after the market close on Wednesday, November 1, 2017.
View HTML